Overview Financials News + Filings Key Docs Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-25-21 | Dec-26-20 | Dec-28-19 |
| | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| KOREA, REPUBLIC OF | 115 | 107 | 96 | |
| GERMANY | 268 | 263 | 153 | |
| UNITED STATES | 551 | 270 | 134 | |
| Mobileye | 1,843 | 1,363 | 956 | 879 |
| Total revenues | 1,869 | 1,386 | 967 | |
| Revenue growth [+] | 34.8% | 43.3% | | |
| KOREA, REPUBLIC OF | 7.5% | 11.5% | | |
| GERMANY | 1.9% | 71.9% | | |
| UNITED STATES | 104.1% | 101.5% | | |
| Mobileye | 35.2% | 42.6% | 8.8% | |
| Other | 13.0% | 109.1% | | |
| Cost of goods sold | 947 | 731 | 591 | |
| Gross profit | 922 | 655 | 376 | |
| Gross margin | 49.3% | 47.3% | 38.9% | |
| Selling, general and administrative [+] | 170 | 168 | 149 | |
| Sales and marketing | 120 | 134 | 116 | |
| General and administrative | 50 | 34 | 33 | |
| Research and development | 789 | 544 | 440 | |
| EBITDA [+] | 530 | 469 | 250 | |
| EBITDA growth | 13.0% | 87.6% | | |
| EBITDA margin | 28.4% | 33.8% | 25.9% | |
| Depreciation | 23 | 17 | 13 | |
| EBITA | 507 | 452 | 237 | |
| EBITA margin | 27.1% | 32.6% | 24.5% | |
| Amortization of intangibles | 544 | 509 | 450 | |
| EBIT [+] | -37 | -57 | -213 | |
| EBIT growth | -35.1% | -73.2% | | |
| EBIT margin | -2.0% | -4.1% | -22.0% | |
| Other income (expense), net | 5 | | 1 | |
| Pre-tax income | -32 | -57 | -212 | |
| Income taxes | 50 | 18 | -16 | |
| Tax rate | | | 7.5% | |
| Net income | -82 | -75 | -196 | |
| Net margin | -4.4% | -5.4% | -20.3% | |
| |
| Basic EPS [+] | ($0.11) | ($0.10) | ($0.26) | |
| Growth | 8.0% | -61.7% | | |
| Diluted EPS [+] | ($0.11) | ($0.10) | ($0.26) | |
| Growth | 8.0% | -61.7% | | |
| |
| Dividends per share | $0.44 | | | |
| |
| Shares outstanding (basic) [+] | 759 | 750 | 750 | |
| Growth | 1.2% | 0.0% | | |
| Shares outstanding (diluted) [+] | 759 | 750 | 750 | |
| Growth | 1.2% | 0.0% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|